Treatment duration as a function of clinician-level patient volume: mechlorethamine treatment for mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)

被引：0
|
作者：
Querfeld, Christiane [1 ]
Pacheco, Theresa [2 ]
Haverkos, Bradley [2 ]
Binder, Gary [3 ]
Angello, James [3 ]
Poligone, Brian [4 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Helsinn Therapeut US, Woodbridge, NJ USA
[4] Rochester Skin Lymphoma Med Grp, Fairport, NY USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-010
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] Clinician-level variation in mechlorethamine treatment duration in mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
    Querfeld, Christian
    Pacheco, Theresa
    Haverkos, Bradley
    Binder, Gary
    Angello, James
    Poligone, Brian
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S8 - S8
  • [2] A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study
    Querfeld, Christiane
    Pacheco, Theresa
    Haverkos, Bradley
    Binder, Gary
    Angello, James
    Poligone, Brian
    FRONTIERS IN MEDICINE, 2021, 8
  • [3] Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
    Crimp, Caitlin
    Gangal, Ameya
    Tarabadkar, Erica S.
    Shinohara, Michi M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3271 - 3279
  • [4] Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
    Denis, Daphne
    Beneton, Nathalie
    Laribi, Kamel
    Maillard, Herve
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2241 - 2251
  • [5] MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION
    D'Agostino, P.
    Lezzi, C.
    Kent, A.
    Sharp, E.
    Schmidt, F.
    Turini, M. M.
    VALUE IN HEALTH, 2019, 22 : S852 - S853
  • [6] Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): "Real-world'' experience from the Prospective Observational Study (PROVe)
    Geskin, Larissa
    Guitart, Joan
    Kim, Ellen
    Sharma, Gaurav
    Zhao, Carol
    Rengarajan, Badri
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB307 - AB307
  • [7] Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel
    Chase, Allister Benjamin
    Markel, Kristen
    Tawa, Marianne C.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (06) : E131 - E139
  • [8] No detectable systemic absorption of topically applied 0.02% and 0.04% chlormethine (CL) gel in patients with mycosis-fungoides cutaneous T-cell lymphoma (MF-CTCL)
    Querfeld, C.
    Scarisbrick, J.
    Quaglino, P.
    Papadavid, E.
    Romero, P. Ortiz
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S109 - S109
  • [9] Schedule frequency of chlormethine gel for patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): A real-world evidence study
    Querfeld, Christiane
    Binder, Gary
    Turini, Marco
    Gor, Deval
    Wassel, Christina L.
    Pashos, Chris
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB77 - AB77
  • [10] Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma
    Talpur, Rakhshandra
    Venkatarajan, Sangeetha
    Duvic, Madeleine
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 591 - 597
12345